CME-Laboratory 61: New European Consensus Recommendations on Dyslipidemia Abstract. The lipid status primarily serves to estimate the risk of atherosclerotic cardiovascular diseases (ASCVD). LDL cholesterol (LDL-C) is the primary target of lipid-lowering therapies. NonHDL cholesterol and apolipoprotein B are secondary targets. The European Cardiology and Atherosclerosis Societies have lowered their treatment targets for all risk groups. Triglycerides and HDL cholesterol are also recommended for risk assessment, but are not therapeutic goals. Lipoprotein (a) is a strongly genetically determined ASCVD risk factor and contains a statin-resistant part of LDL-C. The quality of laboratory diagnostics for all lipid risk factors is in need of improvement due to the fact that it is too dependent on methods and in view of the indication of new and expensive lipid-modifying therapies.